checkAd

    Nanosphere, ein Gewinner im Molekulardiagnostikmarkt? - 500 Beiträge pro Seite

    eröffnet am 09.03.12 13:12:41 von
    neuester Beitrag 12.02.14 18:17:49 von
    Beiträge: 28
    ID: 1.172.927
    Aufrufe heute: 0
    Gesamt: 2.748
    Aktive User: 0

    ISIN: US63009F2048 · WKN: A14RM1
    1,6900
     
    USD
    0,00 %
    0,0000 USD
    Letzter Kurs 01.07.16 Nasdaq

    Werte aus der Branche Biotechnologie

    WertpapierKursPerf. %
    2,3400+57,58
    2,5600+34,03
    6,4000+28,00
    1,0900+23,86
    0,7995+23,00
    WertpapierKursPerf. %
    0,6279-16,06
    6,9900-19,00
    0,9000-20,35
    18,100-22,22
    0,7031-25,98

     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 09.03.12 13:12:41
      Beitrag Nr. 1 ()
      Hallo zusammen,

      eigentlich halte ich mich fern von Firmen mit solchen Namenskürzel wie "Nano plus xxx".
      Aber hier lohnt sich evtl. mal ein Blick auf dieses noch kleine Unternehmen zu werfen.
      Die Wahl des Forum Biotech statt Nano, liegt auch auf der Hand, wenn man sich mit dem Unternehmen etwas näher beschäftigt.


      Eine aktuelle Empfehlung habe ich auch dabei:

      06.02., 12:19 GLOBAL BIOTECH INVESTING
      (aktiencheck.de AG) - Mit der Aktie von Nanosphere (ISIN US63009F1057/ WKN A0M6DC) können Anleger nach Meinung der Experten von "Global Biotech Investing" auf das am schnellsten wachsende Segment innerhalb der Diagnostik-Sparte setzen.
      Nanosphere verfüge über eine eigene Plattformtechnik, die den Namen "Verigene System" trage. Damit könne man Patienten, Ärzten und Krankenhäusern schnell sowie kostengünstig Informationen über diverse Krankheitsbilder geben.

      Der gesamte Diagnostikmarkt habe ein Volumen von circa 41 Mrd. USD. Daran habe der Molekulardiagnostikmarkt mit rund 4 Mrd. USD noch einen relativ kleinen Anteil. Dieser wachse aber jährlich zwischen 10% und 15%.

      Nanosphere habe sich inzwischen auf dem US-Markt etabliert. In 2011 sei dann die Expansion in erste Länder Europas erfolgt. In Kürze wolle man auch die attraktiven Märkte in Frankreich und Deutschland angehen. Vor diesem Hintergrund würden die Analysten von Stephens für 2013 einen Umsatzanstieg von 2,51 auf 38,65 Mio. USD prognostizieren und der Verlust dürfte von 0,95 USD auf 0,47 USD je Aktie halbiert werden. Die Gesellschaft verfüge über Barmittel in Höhe von 47 Mio. USD (per 30.09.2011), womit man bis 2013 liquide sei.

      Zwar habe sich der Wert von seinen 52-Wochentiefs inzwischen etwas lösen können, doch mit einem Kursziel von 5 USD verfüge der Titel immer noch über ein Potenzial von 170%.

      Nach Meinung der Experten von "Global Biotech Investing" sollen sich mutige Investoren ein paar Stücke der Nanosphere-Aktie ins Depot holen. (Ausgabe 03 vom 06.02.2012) (06.02.2012/ac/a/a)

      Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.
      Avatar
      schrieb am 09.03.12 13:57:06
      Beitrag Nr. 2 ()
      von der website www.nanosphere.us der Investor Overview:

      Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Our proprietary nanoparticle technology simplifies the ability to perform molecular diagnostic tests, achieves ultra-sensitive protein detection at limits beyond current diagnostic technologies, provides the ability to multiplex, or run multiple tests at the same time on the same sample, and enables the development of a broad menu of test assays to be performed on a single platform. We are currently developing diagnostic tests for a variety of medical conditions including cancer, neurodegenerative, cardiovascular and infectious diseases, as well as pharmaco-genomics, or tests for personalized medicine. There is a growing demand among laboratories to implement molecular diagnostic capabilities, but the cost and complexity of existing technologies and the need for specialized personnel and facilities have limited the number of laboratories with these capabilities. We believe that the Verigene System’s ease of use, rapid turnaround times, relatively low cost and ability to support a broad test menu will simplify work flow and reduce costs for laboratories already performing molecular diagnostic testing and allow a broader range of laboratories, including those operated by local hospitals, to perform molecular diagnostic testing. Our ability to detect proteins, which is at least 100 times more sensitive than current technologies, may enable earlier detection of and intervention in diseases associated with known biomarkers and the introduction of tests for new biomarkers that exist in concentrations too low to be detected by current technologies.
      Avatar
      schrieb am 01.05.12 09:40:04
      Beitrag Nr. 3 ()
      Nanosphere Enters Into Marketing and Distribution Agreement in Europe With Thermo Fisher Scientific

      NORTHBROOK, Ill., April 30, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today announced that it entered into a marketing and distribution agreement with Thermo Fisher Scientific Inc. for markets in Germany, Austria and France. Thermo Fisher, the world leader in serving science, has a broad portfolio of products for microbiological applications.

      Nanosphere previously received the CE mark to sell the Verigene® System and a number of assays targeted at the microbiology market segment, a rapidly growing field in which Thermo Fisher has a significant market presence.

      "Thermo Fisher's marketing, distribution and customer support expertise combined with the unique ability of Nanosphere's Verigene System to detect multiple targets in a single, automated test creates a significant competitive advantage in building a major presence in these key European markets," said Michael McGarrity, Nanosphere's chief commercial officer.

      "The agreement will focus on Verigene products that provide rapid identification of infectious diseases and associated drug resistance, arming physicians and hospitals with clinically actionable results that improve patient care and reduce the cost of treating critical illnesses," commented Paul James, Thermo Fisher's European vice president and general manager for microbiology. "We are excited to be working with the Nanosphere team to bring these innovative molecular diagnostic products to our customers for the first time. Together with our existing range of Thermo Scientific microbiology products, they provide a comprehensive solution to diagnosis of serious infectious disease," concluded James.

      With the commencement of this agreement, Nanosphere will possess distribution agreements in all of the major markets in Europe, a key step in its global expansion strategy.

      About Nanosphere, Inc.

      Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
      Avatar
      schrieb am 01.05.12 09:43:52
      Beitrag Nr. 4 ()
      noch etwas zu Thermo Fisher:

      Overview
      Thermo Fisher Scientific (NYSE: TMO) is the world leader in serving science. The company enables its customers to make the world healthier, cleaner and safer by providing analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics.

      With annual sales of $12 billion, Thermo Fisher Scientific has over 39,000 employees and serves more than 350,000 customers in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental, industrial quality and process control settings.

      The company delivers the industry’s broadest selection of analytical instruments, equipment, consumables and laboratory supplies. Its growing portfolio of products includes innovative technologies for mass spectrometry, elemental analysis, molecular spectroscopy, sample preparation, informatics, fine and high-purity chemistry production, cell culture, RNA interference analysis and immunodiagnostic testing, as well as air and water quality monitoring and process control. The company also gives its customers the most convenient purchasing options, including a direct sales force of 7,500 professionals, catalogs and e-commerce.
      Avatar
      schrieb am 01.05.12 19:07:32
      Beitrag Nr. 5 ()
      Nanosphere Announces First Quarter 2012 Results

      NORTHBROOK, Ill., May 1, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the first quarter ended March 31, 2012.

      Revenues for the first quarter 2012 were $1.3 million compared to $0.6 million for the same period 2011. Higher revenue in the first quarter 2012 was attributable to new customer placements and increased shipments of respiratory virus cartridges.

      "Our business has achieved an inflection point with new customer placements that will drive significant revenue growth in 2012," commented William Moffitt, Nanosphere's president and chief executive officer. "We are excited about the progress we are making to expand our test menu that will accelerate our growth over the coming quarters."

      Costs and operating expenses decreased from $9.5 million in the first quarter of 2011 to $9.4 million in the first quarter of 2012, driven by reductions in stock compensation and administrative expenses, offset partially by volume driven increases to cost of sales.

      Net loss for the first quarter of 2012 was $8.1 million as compared with $8.9 million for the same period in 2011.

      Cash flow from operating activities in the first quarter of 2012 was negative $7.5 million as compared to negative $9.6 million in first quarter of 2011. Cash and equivalents at March 31, 2012 were $31.8 million.

      Conference Call Details

      The company will hold a live conference call and webcast for investors on Tuesday, May 1, 2012 at 10:00 A.M., Eastern Time. The teleconference can be accessed by dialing 888-713-4216 (U.S./Canada) or 617-213-4868 (international), participant code 20069766. The call will also be broadcast live over the Internet and can be accessed by interested parties at the Investor Relations tab on the Nanosphere website: www.nanosphere.us. For interested individuals unable to join the call or webcast, a replay will be available through May 8, 2012 by dialing 888-286-8010 or for international calls 617-801-6888, pass code 83184684, or on the company's website.

      About Nanosphere, Inc.

      Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for detection of life threatening infections and cardiovascular diseases. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

      Trading Spotlight

      Anzeige
      Der Final Countdown: Hier heute noch rein!? Große Meldung angekündigt…mehr zur Aktie »
      Avatar
      schrieb am 30.06.12 10:33:11
      Beitrag Nr. 6 ()
      Nanosphere Receives FDA Authorization to Market Its Gram-Positive Blood Culture Test
      First of Its Kind Test to Launch Immediately

      NORTHBROOK, Ill., June 27, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today the U.S. Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the automated sample-to-result Verigene® System.

      The BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat.

      With a single automated test, the Verigene BC-GP test provides fast genus and species level detection for a broad panel of clinically significant gram-positive bacteria. The BC-GP test also detects several crucial markers for antimicrobial resistance, including the mecA, vanA, and vanB genes, which confer resistance to the antibiotics methicillin/oxacillin and vancomycin. Rapid detection of these antimicrobial resistance markers provides vital information for clinicians to determine the best treatment for bloodstream infections.

      "With the BC-GP test, patients suspected of deadly infections can now get a first-ever diagnostic tool for detecting disease-causing bacteria while simultaneously determining antibiotic resistance within the critical timeframe for making and adjusting initial treatment," said William Moffitt, Nanosphere's Chief Executive Officer.

      The BC-GP test provides identification of bacteria and antimicrobial resistance genes from gram-positive blood culture bottles within two and a half hours, as compared with current microbiological methods, which can take up to two to three days.

      Rapid and accurate identification of bacteria and resistance markers is critical in guiding appropriate antibiotic treatment. Studies show delayed administration of appropriate antibiotics is associated with a 7.6% decrease in survival rate for each hour therapy is delayed.1 Rapid molecular testing of blood cultures reduces this time, with associated hospital cost savings of up to $21,000 per patient.2

      The sample-to-result BC-GP test automates the steps of bacterial DNA extraction and target detection on the Verigene System.

      The ease-of-use and fast turnaround time of the BC-GP test allow hospitals of any size to benefit from the speed and accuracy of automated molecular testing. In addition to its gram-positive blood culture test, Nanosphere is currently developing a test for gram-negative blood cultures that will provide genus, species, and resistance detection on the same automated platform. These tests are part of a comprehensive infectious disease test menu, including the multiplexed Verigene RV+ respiratory virus test cleared by the FDA in 2011, as well as tests for C. difficile and a panel of enteric bacterial and viral pathogens that Nanosphere plans to submit for FDA clearance in 2012.

      About Bloodstream Infections

      Septicemia is associated with more than 1.6 million hospitalizations per year in the United States and is the most expensive cause of hospitalization totaling $15.4 billion in aggregate hospital costs.3 Septicemia occurs when a pathogenic microorganism, usually a bacterium or a fungus, enters the bloodstream and causes an inflammatory immune response. Because bloodstream infections and septicemia are pervasive problems associated with high mortality rates, timely delivery of appropriate treatment is essential.

      Bloodstream infections with gram-positive bacteria are often complicated by antimicrobial resistance. The inability to rapidly identify resistant strains of pathogenic bacteria has led to antimicrobial use that is often ineffectual, wasteful, or bears risk of proliferating resistant strains. Rapid identification of both organism and resistance is essential to implementing efficient and appropriate therapy.4

      Gram-positive bacteria are also a common source of contamination during blood draws. Contaminant species are frequently responsible for false-positive blood cultures that lead to inappropriate antimicrobial use.5 Patients with contaminated blood culture bottles are often presumptively treated for bloodstream infections for several days until the organism can be identified as a contaminant using conventional biochemical methods. Patients with false-positive blood culture results triggered by contaminants have hospitalization costs more than $8,000 higher than patients with true negative blood culture results.6 Due to the large burden of infections and contaminants due to gram-positive bacteria, rapid identification of bacteria isolated from blood cultures is a primary healthcare concern.

      About Nanosphere, Inc.

      Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, for multiplexed infectious disease, genetic, and ultra-sensitive protein testing. This easy-to-use platform offers laboratories a convenient, simple, and cost-effective solution for highly sensitive nucleic acid and protein testing. Nanosphere is based in Northbrook, IL.

      For additional information regarding Nanosphere's infectious disease products, please contact Nanosphere at IDtesting@nanosphere.us or visit www.nanosphere.us.
      Avatar
      schrieb am 08.07.12 18:26:16
      Beitrag Nr. 7 ()
      Jefferies ups NSPH's price target to $5/share from $2.

      Da ist noch etwas Luft bis $5 :)
      Avatar
      schrieb am 08.08.12 10:58:08
      Beitrag Nr. 8 ()
      Nanosphere Announces Second Quarter 2012 Results
      Tue August 7, 2012 8:00 AM | about: NSPH

      Gram-positive blood culture test cleared by the FDA on June 27th

      Entered into marketing and distribution agreement in Europe with Thermo Fisher Scientific (refer to Nanosphere's (NSPH) April 30th press release)

      25 systems shipped in quarter; 166 cumulative systems placed

      Revenue of $1.3 million compared to $0.5 million for the same quarter last year

      NORTHBROOK, Ill., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the second quarter ending June 30, 2012.

      Revenues for the second quarter 2012 were $1.3 million compared to $0.5 million for the same period 2011. Revenue growth was attributable to new customer placements of the VerigeneSP System.

      "As previously stated in the release of our preliminary quarterly results, we shipped 25 systems to new customers, bringing our cumulative number of systems placed to 166. We believe that our second quarter results were largely driven by the market's enthusiasm and anticipation of our gram-positive test, which is the only test that identifies bacteria and antimicrobial resistant genes from a positive blood culture in hours as opposed to days," commented William Moffitt, Nanosphere's president and chief executive officer. "Given the clearance came in during the final days of the second quarter, we are particularly optimistic about our prospects for achieving the previously announced 40 to 60 projected system placements in the third quarter."

      Gross profit for the quarter ending June 30, 2012 was $461,000 or 34% of revenues, compared with $135,000 or 27% of revenues for the same period in 2011. System sales volume increased significantly this quarter and gains in efficiencies in manufacturing were achieved, resulting in the improvement of gross margin.

      Operating expenses increased from $8.6 million in the second quarter of 2011 to $8.9 million in the second quarter of 2012, driven primarily by the expansion of our commercial organization to support our rapidly growing customer base.

      Net loss for the second quarter of 2012 was $8.4 million, equivalent to the same period in 2011.

      "With the acceleration of system sales this year and the continued improvement in gross margin, we are highly confident in our ability to better leverage our R&D and SG&A expense base and accelerate our progress on the path to achieve profitability," said Roger Moody, Nanosphere's chief financial officer.

      Cash and equivalents at June 30, 2012 were $23.7 million. In July 2012, the company completed an underwritten public offering of common stock that added $26.9 million net proceeds. On a pro forma basis, cash and equivalents at June 30, 2012 was $50.6 million.

      Conference Call Details

      The company will hold a live conference call and webcast for investors on Tuesday, August 7, 2012 at 10:00 A.M., Eastern Time. The teleconference can be accessed by dialing 888-679-8034 (U.S./Canada) or 617-213-4847 (international), participant code 48059307. The call will also be broadcast live over the Internet and can be accessed by interested parties at the Investor Relations tab on the Nanosphere website: www.nanosphere.us . For interested individuals unable to join the call or webcast, a replay will be available through August 14, 2012 by dialing 888-286-8010 or for international calls 617-801-6888, pass code 17470166, or on the company's website.

      About Nanosphere, Inc.

      Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for detection of life threatening infections and cardiovascular diseases. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us .
      Avatar
      schrieb am 08.08.12 11:02:00
      Beitrag Nr. 9 ()
      Aus dem Earning Call Transkript vom 07.08.2012:

      And then last question from me and I'll jump back in the queue here. It's one for Bill. I realize that we're only a little over a month into the quarter. Obviously it seems like you guys are generating a lot of interest in Verigene based on what your team is looking like HCC [ph]. Bill, can you talk a little bit to the level of confidence you have in the 40 to 60 unit placements. I know it's not characteristic of you guys to talk about business quarter to date or anything like that but just give us some sense as to kind of what you're thinking? Thank you.

      Bill Moffitt

      I'd say that the activity we see in the market, the pace at which we're bringing up the previously installed base, the number of new customers coming in, the flow through the pipeline, sort of all of these data points combine to give us good confidence that we will hit the range we have previously forecasted.


      Klingt so weit ganz gut :cool:
      Avatar
      schrieb am 01.11.12 17:05:45
      Beitrag Nr. 10 ()
      Nanosphere Test Accurately Detects a Broad Panel of Bacterial Targets and Resistance Determinants Directly From Blood Culture

      Cleveland Clinic Study Demonstrates Speed and Accuracy of Nanosphere's Verigene Gram-Positive Blood Culture Test


      NORTHBROOK, Ill., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Nanosphere's (Nasdaq:NSPH) Verigene Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) (IUO), based on the company's proprietary array-based nanoparticle technology, demonstrated overall sensitivity and specificity of 99%, respectively, for the detection of a broad panel of gram-positive bacteria from positive blood cultures, according to a recent study. The BC-GP Test also correctly detected the presence or absence of genes encoding vancomycin resistance in Enterococcus spp. and methicillin resistance in Staphylococcus aureus or S. epidermidis. Researchers concluded that the test, which required less than 5 minutes of user hands-on time, provided accurate organism identification and detection of resistance genes compared to routine laboratory methods.

      The investigator-initiated study, showcased in an oral presentation Saturday, October 20 at the inaugural IDWeek™ in San Diego, California, was conducted by Dr. Sandra Richter and colleagues at the Cleveland Clinic in Cleveland, Ohio. Nanosphere funded the research.

      Rapid identification of pathogenic bacteria from blood cultures can greatly reduce length of hospital stay and improve patient outcomes. Benefits of rapid diagnosis are widely recognized and include increased survival rates, decreased costs of patient care, and reduced dosage of unnecessary antibiotics. Current microbiological culture techniques take 24 – 48 hours to identify bacterial pathogens and determine their resistance or susceptibility to common antibiotics.

      Recently FDA-cleared, the BC-GP Test (IVD) notably expands Nanosphere's automated sample-to-result Verigene® platform to include an infectious disease test capable of rapid detection of bacteria that can cause deadly bloodstream infections. The automated BC-GP Test detects 12 bacterial targets and 3 antibiotic resistance targets in less than two and a half hours with less than 5 minutes hands-on time. The Respiratory Virus Plus Nucleic Acid Test (RV+) is an FDA-cleared in vitro diagnostic test for the detection of multiple respiratory viruses and virus subtypes. A sample-to-result test for C. difficile is currently pending FDA review, while tests for gram-negative blood cultures and enteric bacteria and viruses are currently in development and in clinical trials, respectively.

      The study abstract, entitled "Identification of Gram Positive Bacteria and Detection of Resistance Determinants from Blood Cultures Using a Microarray-Based Assay" can be accessed at https://idsa.confex.com/idsa/2012/webprogram/start.html and will be published through IDWeek™ Press at the conclusion of the conference.
      Avatar
      schrieb am 11.11.12 12:36:35
      Beitrag Nr. 11 ()
      Press ReleaseNanosphere Announces Third Quarter 2012 Results
      50 new VerigeneSP system placements double over prior quarter
      C. difficile assay filed with FDA
      FDA categorizes blood stream gram-positive test as CLIA moderate complexity

      NORTHBROOK, Ill., Nov. 7, 2012 (GLOBE NEWSWIRE) -- Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, today reported financial results for the third quarter ending September 30, 2012.

      "Continuing positive momentum marked the quarter as we shipped 50 VerigeneSP new customer placements, the highest number in any single quarter to date," said William Moffitt, Nanosphere president and chief executive officer. "The acceleration in product placements was driven primarily by FDA clearance of our gram-positive blood culture test at the end of the second quarter. We are very encouraged with the market's response to the introduction of the gram-positive test and are working diligently to get additional content approved for VerigeneSP, including our c. difficile, gram-negative and enteric panels."

      Financial Highlights
      50 new VerigeneSP systems were placed during the quarter, bringing the cumulative number of systems placed to 216.
      Revenues for the third quarter 2012 were $865,000 compared to $556,000 for the same period 2011, driven primarily by increased consumable sales to new customers. Third quarter revenue did not include meaningful blood stream infection gram-positive sales as most new placements have taken approximately 90 days to validate the assay, after which revenue recognition commences.
      R&D expenses decreased to $4.6 million for the quarter from $5.8 million in the same period in 2011 due to reduced spending on clinical trials and reduced patent-related legal expenses.
      SG&A expenses increased in the second quarter to $4.4 million from $3.8 million in the third quarter of 2011 due to increased expenses from the expansion of our sales and customer support teams.
      Total operating expenses were $9.0 million in the quarter, down from $9.7 million in the same period of 2011.
      Net loss for the third quarter of 2012 was $8.7 million, down from $9.5 million for the same period in 2011.
      Cash and cash equivalents as of September 30, 2012 were $41.9 million.
      In July 2012, the company completed a public offering of common stock that added $27 million in net proceeds.

      Clinical Highlights
      The FDA categorized Nanosphere's Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the Verigene System as a moderate complexity test under the Clinical Laboratory Improvement Amendments (CLIA) program, allowing for expanded decentralization of the Verigene testing platform.
      The Company submitted a 510(k) for its Clostridium difficile assay to the FDA. Initial comments and questions are expected before year end.

      Conference Call Details

      The company will hold a live conference call and webcast for investors on Wednesday, November 7, 2012 at 5:00 P.M., Eastern Time. The teleconference can be accessed by dialing 888-680-0879 (U.S./Canada) or 617-213-4856 (international), participant code 46512458. The call will also be broadcast live over the Internet and can be accessed by interested parties at the Investor Relations tab on the Nanosphere website: www.nanosphere.us. For interested individuals unable to join the call or webcast, a replay will be available through November 14, 2012 by dialing 888-286-8010 or for international calls 617-801-6888, pass code 86076200, or on the company's website.

      About Nanosphere, Inc.

      Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene® System, for detection of life threatening infections and cardiovascular diseases. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.
      Avatar
      schrieb am 14.02.13 17:12:14
      Beitrag Nr. 12 ()
      Nanosphere's CEO Discusses Q4 2012 Results - Earnings Call Transcript
      +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++

      February 13, 2013 | about: NSPH

      Nanosphere, Inc. (NSPH) Q4 2012 Earnings Call February 13, 2013 5:00 PM ET

      Operator

      Good day, ladies and gentlemen, and welcome to the Nanosphere Fourth Quarter and Full Year 2012 Earnings Conference Call. My name is Jeff and I will be your coordinator for today. At this time all participants are in listen-only mode. Later we will facilitate a question-and-answer session (Operator Instructions). As a reminder this conference is being recorded for replay purposes.

      Before we begin, Nanosphere would like to state that certain statements made during this conference call which are not based on historical facts may be deemed to constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 because these forward-looking statements involve known and unknown risks and uncertainties, these are important factors that could cause actual results, events or developments to differ materially from those impressed or implied by these forward-looking statements. Such factors include those described from time to time in Nanosphere's filings with the United States Securities and Exchange Commission. Please note that Nanosphere undertakes no duty to update this information.

      I would now like turn the presentation over to your host for today Mr. Michael McGarrity, President and Chief Executive Officer. You have the floor sir.

      Michael K. McGarrity - President and Chief Executive Officer
      Thanks Jeff, and thanks to all of you for joining us for our Q4 and full-year results call for 2012. With me today is Roger Moody, Chief Financial Officer of the company. I would like to begin my comments with the organizational announcement released as part of our earnings report. On behalf of all of our Nanosphere employees, I would like to wish Bill Moffitt and thank him for his years of dedicated service with the company. Also on behalf of our employees and customers, I want to emphasize her excitement as we embark on the next chapter of growth as a company.

      Over the years our employees have worked tirelessly, to take the core technology and unlock its potential. That potential ranges from aiding and diagnosis and treatment of a variety of disease states ranging from high risk genetic disorders to complex sepsis syndromes to acute coronary syndrome, heart failure and cancer. While this broad focus might have compromised our ability to execute and deliver results, we have now defined a clear path to growth in microbiology fueled by our expanding menu of tests. Evidence of this focus is our Q4 results in which we had 56 new customer placements and nearly doubled revenue from Q3 to $1.6 million. We now have installed or are in the process of installing Verigene Systems and microbiology laboratories across the US, running our Respiratory Virus Assays, our Gram-Positive Blood Culture Assay, our C. difficile assays or a combination of our expanding menu.

      Our blood culture customer validations are progressing well. My experience in the field with our sales reps and customers, in addition to our team's significant clinical study work validates this progress. And I thought it would be helpful to provide color on this aspect of our revenue ramp.

      Our customers can generally be grouped into three categories, the first set of customers in which our microbiology director is able to drive the process in the utilization from the validation data generated by the laboratory. The second set of customers that require validation data to be presented to additional organizational disciplines, like pharmacy, infectious disease, and critical care. Finally, customers that are conducting perspective type validations and their patient population with some interventional and economic outcome analysis.
      Avatar
      schrieb am 12.06.13 16:45:23
      Beitrag Nr. 13 ()
      http://www.azonano.com/news.aspx?newsID=27347

      Hitachi High-Tech to Market Nanosphere's Molecular Diagnostics Tests in Japan
      Published on May 14, 2013 at 7:28 AM
      Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, announced today it has signed a distribution and collaboration agreement with Hitachi High-Technologies Corporation (Hitachi High-Tech).


      zitat:http://finance.yahoo.com/mb/NSPH/#mbt=Japan%25202nd-Larg%25u…

      Japan 2nd-Largest Medical Device Market in the World.And Japan is the 3rd-largest importer of medical devices in the world.
      Japan External Trade Organization: How U.S. Companies Are Positioned to Get Ahead of Upcoming Shifts in Japan
      ========================================================================================
      A shift comes from a push within the Japan healthcare industry to provide more diagnostic services through local physicians than hospitals. Currently, people in Japan visit large university hospitals for nearly all ailments, including the common cold. To more efficiently use hospital resources, healthcare providers are encouraging patients to seek basic care from local physicians. This upcoming shift is expected to increase demand for diagnostic equipment, a sector in which U.S. companies have a strong lead. Japan receives 60% of its medical equipment imports from the U.S. Of those U.S. imports, 72% consist of diagnostic equipment. In 2008, reimbursement price revisions were made to medical devices. The latest revisions in reimbursement price made several positive allowances in favour of innovative medical devices, by raising reimbursement prices in order to provide an incentive for the development of more such devices and use in the country’s healthcare system. Imports rose by 8.1% to reach a new record high of US$11.6 billion in 2011. I'm calling the Hitachi / Nanosphere deal a 'grand-slam at the top of the 1st inning'. The near and long-term future is blazing bright :)
      Avatar
      schrieb am 11.07.13 17:32:03
      Beitrag Nr. 14 ()
      bin schon ganz gespannt, ob die erwartungen der halbjahreszahlen erfüllt werden können. falls diese positiv sind und zusätzlich noch ein guter ausblick folgt, könnte diese aktie in den nächsten jahren ein überflieger werden...
      Avatar
      schrieb am 17.07.13 09:58:55
      Beitrag Nr. 15 ()
      “Nanosphere’s pathogen identification system shows promise………
      Verigene system is an upcoming diagnostic biotech that has got incredible potential”

      http://www.financialstrend.com/nanosphere-inc-nasdaqnsph-pre…
      Avatar
      schrieb am 17.07.13 13:56:15
      Beitrag Nr. 16 ()
      die Erwartungen zu den Zahlen, Quelle 4-traders.com

      Revenue Revisions


      Evolution of the average goal on NANOSPHERE, INC
      Avatar
      schrieb am 18.07.13 18:38:26
      Beitrag Nr. 17 ()
      die Zahlen werden wohl um den 6.8. kommen.....

      die laufenden jährlichen Betriebsausgaben etwa konstant 33-41 mio $

      Total operating expenses at Nanosphere have been fairly steady, and the company hasn't made any announcements that suggest dramatic increases in the near term. At the company's current rate of revenue growth, existing cash on hand should be enough to bring the company to positive cash flows.

      http://seekingalpha.com/article/1534732-nanosphere-there-s-g…
      Avatar
      schrieb am 26.07.13 14:36:51
      Beitrag Nr. 18 ()
      hier mal das angepeilte Marktgeschehen:

      Each year in the United States, there are more than 1.5 million hospital stays associated with bloodstream infections and septicemia, resulting in nearly 100,000 deaths and over $15 billion in healthcare costs [1]. Treatment of these serious bacterial infections in clinical practice is often complicated by antibiotic resistance, which has been associated with prolonged hospital stays, higher health care costs and increased mortality. The recent emergence of CREs is especially troubling, as there are very few antibiotic alternatives available to treat these bacteria.

      http://www.prweb.com/releases/2013/7/prweb10925090.htm

      http://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf

      http://de.wikipedia.org/wiki/Sepsis
      Avatar
      schrieb am 08.08.13 16:30:51
      Beitrag Nr. 19 ()
      Nanosphere (NSPH) Q2 comes in mixed,....... It lowered its full-year revenue and customer placements guidance however, now projecting FY13 revenue of $10M to $11M and 150 to 200 customer placements. That number is down from its May view of $13M to $15M in revenue and 200 to 250 customer placements.........

      http://seekingalpha.com/currents/post/1199892

      Marke 1,50 eur
      Avatar
      schrieb am 14.08.13 18:31:34
      Beitrag Nr. 20 ()
      ........Cash flow for the second quarter of 2013 was positive $7.6 million including a $16.5 million increase from financing activities and $8.8 million decrease from operating activities. Cash at June 30, 2013 was $32.0 million...........

      SEC Filing, Date of Report: August 6, 2013
      Avatar
      schrieb am 23.08.13 18:20:05
      Beitrag Nr. 21 ()
      Nsph offensiv- acht Studien (USA, Brüssel, Japan) werden präsentiert:

      Early and accurate diagnosis, particularly for critical bloodstream, blood cultures and gastrointestinal infections

      http://www.azonano.com/news.aspx?newsID=28107
      Avatar
      schrieb am 23.08.13 19:06:30
      Beitrag Nr. 22 ()
      Partner Thermo Fisher

      Avatar
      schrieb am 29.08.13 19:26:34
      Beitrag Nr. 23 ()
      Avatar
      schrieb am 18.10.13 12:47:17
      Beitrag Nr. 24 ()
      >> The global biomarkers market shows a high growth potential and accounts for $17.5 billion in 2013. It is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018

      from http://www.businesswire.com/news/home/20131014005994/en/Rese…
      Avatar
      schrieb am 20.10.13 12:19:33
      Beitrag Nr. 25 ()
      alternative zu epigenomics / heiß gelaufen/
      u evotec

      NSPH billig, Kurs gegenüber Max halbiert

      eine KE von Sept wurde zu 1,75 $ plaziert,
      letzter Kurs 2,05$
      Avatar
      schrieb am 27.10.13 12:59:18
      Beitrag Nr. 26 ()
      zur Technik der Goldnanobälle bei Nanosphere, Durchmesser 13-20 nm

      http://www.nanosphere.us/page/gold-nanoparticle-technology

      hier eine andere Anwendung für Goldnanopartikel, Durchmesser um 10 nm

      recycling CO2, converting carbon dioxide to carbon monoxide

      http://www.rdmag.com/news/2013/10/gold-nanoparticles-give-ed…
      Avatar
      schrieb am 18.11.13 11:05:16
      Beitrag Nr. 27 ()
      Nanosphere Inc.'s stock rallied 4.15% on Wednesday, closing at $2.26, after oscillating between $2.12 and $2.27 during the trading session. A total of 2.02 million shares were traded, which is above the daily average volume of 0.59 million. The company's shares have gained 10.24% in the previous three months and 17.10% in the last one month, outperforming the S&P 500, which has gained 5.18% and 4.63% during the respective periods. Additionally, Nanosphere Inc.'s stock is trading above its 50-day moving average of $2.00

      Q=4-traders.com
      Avatar
      schrieb am 12.02.14 18:17:49
      Beitrag Nr. 28 ()
      Nanosphere Announces Fourth Quarter and Full Year 2013 Results and 2014 Guidance

      NORTHBROOK, IL -- (Marketwired) -- 02/12/14 -- Nanosphere, Inc. (NASDAQ: NSPH)

      Corporate Highlights and Guidance:

      Thirty-five new customer placements in fourth quarter and 161 for 2013
      Record fourth quarter and fiscal year revenue of $3.4 million and $10.0 million, respectively
      Gram-Negative Blood Culture Test recently cleared by FDA to address urgent public health threat, and Enteric Pathogens Test for gastrointestinal infections recently submitted to FDA
      2014 guidance set at $19-$21 million in revenue and approximately 200 new customer placements

      Nanosphere, Inc. (NASDAQ: NSPH), a company enhancing medicine through targeted molecular diagnostics, today reported financial results for the fourth quarter and fiscal year ended December 31, 2013, and provided guidance for 2014.

      As the Company previously announced, Nanosphere achieved record revenues for the full year and fourth quarter of 2013. Revenues for the fourth quarter and full year 2013 were $3.4 million and $10.0 million, respectively, compared to $1.6 million and $5.1 million in the fourth quarter and full year 2012. This doubling of year-over-year revenue growth was driven predominantly by U.S.-based microbiology laboratories adopting the Verigene® System and Nanosphere's growing menu of infectious disease tests.

      "We are pleased to see continued adoption of our expanding menu of infectious disease tests, as they are demonstrating significant value in improving patient care, preventing antibiotic resistance and reducing healthcare costs," said Michael McGarrity, Nanosphere's president and chief executive officer. "Our recent regulatory milestones, consisting of FDA clearance for our Verigene® Gram-Negative Blood Culture Test, and submission to the FDA of our Verigene Enteric Pathogens Test for gastrointestinal infections, enhance our ability to deliver value to our customers and patients, while contributing to Nanosphere's continued growth."

      For the fiscal year ending December 31, 2014, the Company currently expects to generate $19-$21 million in revenue and approximately 200 new customer placements.

      Costs and operating expenses were $43.7 million in 2013 as compared to $38.0 million in 2012. Costs of sales increased to $6.4 million in 2013 from $3.5 million in 2012, driven by increased volume. Gross margins increased to 36% in 2013 from 30% in 2012. Sales, general and administrative expenses in 2013 increased to $18.7 million from $14.7 million as field sales and customer support teams were expanded. Research and development expenses decreased from $19.7 million in 2012 to $18.6 million in 2013 due primarily to reduced material spending on development projects and the capitalization of certain raw material inventory items that were expensed in the previous fiscal year.

      Net loss for 2013 was $34.6 million, compared with $32.9 million in 2012. Net loss for the fourth quarter of 2013 was $8.8 million compared with $7.6 million for the same period in 2012 and $9.4 million in the third quarter of 2013.

      Cash increased $8.3 million in 2013 due primarily to financing activities of $43.7 million offset by cash used in operations of $34.0 million and cash used in investing activities of $1.4 million. Cash flow for the fourth quarter of 2013 was negative $7.8 million as compared with negative $8.8 million in the same quarter of 2012. Cash at December 31, 2013 was $41.5 million.


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      Nanosphere, ein Gewinner im Molekulardiagnostikmarkt?